Kopran Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹194Cr
- +16.9% YoY
- +64.8% QoQ
- Net profit
- ₹9Cr
- −10.2% YoY
- Turned profitable QoQ
- Margin
- 9.14%
- −2.8 pp YoY
- +13.6 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Kopran Ltd Q3 FY26 key numbers
- Revenue
- Year-on-year revenue increase: Rs. 2,804 lakhs (~16.87% increase).
As stated in Kopran Ltd's Q3 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Kopran Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY 2025-26 Revenue from Operations: Rs. 19,428 lakhs (Page 5). Q3 FY 2025-26 Financials:.
From Kopran Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY 2025-26 Revenue from Operations: Rs. 19,428 lakhs (Page 5)
- Q3 FY 2024-25 Revenue from Operations: Rs. 16,624 lakhs (Page 5)
- Year-on-year revenue increase: Rs. 2,804 lakhs (~16.87% increase)
- Formulations Q3 FY 2025-26 revenue: Rs. 9,231 lakhs (Page 9)
2 more points from Kopran Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Strategic focus on capacity expansion mentioned under "STRATEGIC IMPERATIVES" (Page 15) without specific amounts or timelines.
- API and R&D facility located at Panoli (Gujarat) noted, implying operational status (Page 15).
- Emphasis on process improvements, automisation of packing lines, and prudent capital allocation stated (Page 15), indicating ongoing investments but without quantified figures or schedules.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.
Kopran Ltd — Quarterly revenue & net profit
Kopran Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 194 | 166 | +16.9% | 118 | +64.8% |
| Operating profit (EBITDA) | 18 | 20 | -10.5% | -5 | — |
| Operating margin | 9.14% | 11.94% | -2.8 pp | -4.48% | +13.6 pp |
| Profit before tax | 11 | 14 | -22.5% | -12 | — |
| Net profit (PAT) | 9 | 10 | -10.2% | -10 | — |
| EPS (₹) | 1.94 | 2.16 | -10.2% | -2.06 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Kopran Ltd Q3 FY26 results?
Q3 FY 2025-26 Revenue from Operations: Rs. 19,428 lakhs (Page 5). Q3 FY 2025-26 Financials:.
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Strategic focus on capacity expansion mentioned under "STRATEGIC IMPERATIVES" (Page 15) without specific amounts or timelines.
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
